93,521 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Simplify Asset Management Inc.

Key Points

• Simplify Asset Management purchased 93,521 shares of Collegium Pharmaceutical during the third quarter, valued at approximately $2.04 million. Several other institutional investors, including Bank of America and Bank of New York Mellon, also recently initiated positions.
• Analyst sentiment remains generally positive but mixed: Collegium has a consensus “Moderate Buy” rating and an average price target of $48.71, despite several recent target cuts and one sell rating.
• Collegium reported quarterly EPS of $1.92, exceeding estimates of $1.72, while revenue reached $199.88 million, up 6.3% year over year. The stock opened at $23.23, well below its 52-week high of $50.79.

Simplify Asset Management Inc. bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 93,521 shares of the specialty pharmaceutical company's stock, valued at approximately $2,041,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Freestone Grove Partners LP bought a new stake in Collegium Pharmaceutical in the 2nd quarter valued at $1,611,000. Globeflex Capital L P acquired a new position in Collegium Pharmaceutical in the 2nd quarter valued at $1,915,000. Bank of America Corp DE acquired a new position in Collegium Pharmaceutical in the 2nd quarter valued at $9,882,000. Empowered Funds LLC bought a new position in Collegium Pharmaceutical during the 2nd quarter worth $2,045,000. Finally, Bank of New York Mellon Corp bought a new position in Collegium Pharmaceutical during the 2nd quarter worth $8,506,000.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings downgraded Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, September 4th. Barclays decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 19th. Piper Sandler reaffirmed a "neutral" rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a "buy" rating and a $49.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $48.71.

Collegium Pharmaceutical Trading Up 1.0%

Shares of NASDAQ:COLL opened at $23.23 on Thursday. The company has a market capitalization of $756.37 million, a P/E ratio of 18.73, a P/E/G ratio of 0.71 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 1 year low of $21.43 and a 1 year high of $50.79. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The business's 50 day simple moving average is $23.47 and its 200 day simple moving average is $33.59.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company's revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $1.68 EPS. On average, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.42 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.